Trial Profile
Phase II Study of BAY 43-9006 in Japanese Patients With Renal Cell Carcinoma,
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Bayer
- 29 Nov 2005 New trial record.